MTSS1 mRNA levels were high in AML with prognostically favorable CBF-rearrangements, and low in AML carrying FLT3-ITD mutations or a PML-RARA fusion, both of which are associated with a poor prognosis under araC/anthracycline based therapy [44, 45]. The gene discussed is MTSS1; the disease is acute myeloid leukemia.